文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

生物标志物联合检测在急性呼吸窘迫综合征诊断与预后评估中的意义

[Significance of combined application of biomarkers in the diagnosis and prognosis assessment of patients with acute respiratory distress syndrome].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2021-01-01
一句话结论联合检测血清CC16与sRAGE诊断ARDS的AUC为0.932,预测住院死亡的AUC为0.900,均优于单独检测。

研究纳入2019年7月至2020年9月天津医科大学朱宪彝纪念医院ICU收治的100例ARDS患者为ARDS组,同期100例非ARDS患者为对照组,检测血清CC16和sRAGE水平并绘制ROC曲线。ARDS组CC16和sRAGE均显著高于非ARDS组(均P<0.01);ARDS死亡组两指标均显著高于存活组(均P<0.01)。联合检测诊断ARDS的AUC为0.932(95%CI 0.900-0.965),预测住院死亡的AUC为0.900(95%CI 0.828-0.972),均优于单独检测。

要点

  • ARDS组血清CC16为38.78±14.70 mg/L、sRAGE为2 470.95±288.70 pg/L,均显著高于非ARDS组(分别为21.87±2.45 mg/L、2 013.22±131.15 pg/L,均P<0.01)。
  • ARDS死亡组CC16为42.02±10.81 mg/L、sRAGE为2 638.34±324.07 pg/L,均显著高于存活组(分别为30.52±9.47 mg/L、2 279.91±163.70 pg/L,均P<0.01)。
  • 联合检测诊断ARDS的AUC为0.932(95%CI 0.900-0.965),灵敏度89.0%、特异度87.6%,优于CC16单独(AUC 0.859,95%CI 0.808-0.911,cut-off 25.76 mg/L)和sRAGE单独(AUC 0.821,95%CI 0.762-0.879,cut-off 2 203.00 pg/L)。
  • 联合检测预测ARDS住院死亡的AUC为0.900(95%CI 0.828-0.972),灵敏度88.7%、特异度84.5%,优于CC16单独(AUC 0.747,95%CI 0.651-0.843,cut-off 32.95 mg/L)和sRAGE单独(AUC 0.819,95%CI 0.737-0.902,cut-off 2 554.50 pg/L)。
  • ARDS组机械通气时间显著长于非ARDS组(15.44±3.04天 vs. 12.61±3.73天,P<0.01),住院病死率更高(38.0% vs. 9.0%,P<0.01),但两组性别、年龄、BMI、APACHEⅡ评分及ICU住院时间无显著差异。

适用人群与场景

  • 2019年7月至2020年9月天津医科大学朱宪彝纪念医院ICU收治的100例ARDS患者(ARDS组)
  • 同期该ICU收治的100例非ARDS患者(对照组)

诊断标准与关键阈值

  • CC16诊断ARDS的最佳cut-off值为25.76 mg/L,sRAGE为2 203.00 pg/L
  • CC16预测ARDS患者住院死亡的最佳cut-off值为32.95 mg/L,sRAGE为2 554.50 pg/L

研究设计与关键结果

  • 研究类型为病例对照研究,纳入ARDS组100例、对照组100例,比较两组及ARDS存活组(62例)与死亡组(38例)的临床指标和血清CC16、sRAGE水平,用ROC曲线评价诊断和预后价值。
  • ARDS组机械通气时间显著长于非ARDS组(15.44±3.04天 vs. 12.61±3.73天,P<0.01),住院病死率更高(38.0% vs. 9.0%,P<0.01);两组性别、年龄、BMI、APACHEⅡ评分、ICU住院时间无显著差异。
  • ARDS死亡组APACHEⅡ评分显著高于存活组(23.55±2.83 vs. 19.40±4.10,P<0.01);两组年龄、BMI、氧合指数、平均动脉压、机械通气时间、ICU住院时间无显著差异。
  • ARDS组血清CC16和sRAGE均显著高于非ARDS组[CC16(mg/L):38.78±14.70 vs. 21.87±2.45,sRAGE(pg/L):2 470.95±288.70 vs. 2 013.22±131.15,均P<0.01]。
  • ARDS死亡组血清CC16和sRAGE均显著高于存活组[CC16(mg/L):42.02±10.81 vs. 30.52±9.47,sRAGE(pg/L):2 638.34±324.07 vs. 2 279.91±163.70,均P<0.01]。
  • CC16和sRAGE单独诊断ARDS的AUC分别为0.859(95%CI 0.808-0.911)和0.821(95%CI 0.762-0.879),最佳cut-off值分别为25.76 mg/L和2 203.00 pg/L;联合检测AUC为0.932(95%CI 0.900-0.965),灵敏度89.0%、特异度87.6%。
  • CC16和sRAGE单独预测ARDS住院死亡的AUC分别为0.747(95%CI 0.651-0.843)和0.819(95%CI 0.737-0.902),最佳cut-off值分别为32.95 mg/L和2 554.50 pg/L;联合检测AUC为0.900(95%CI 0.828-0.972),灵敏度88.7%、特异度84.5%。

证据类型、等级与局限

  • 证据类型:病例对照研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为血清CC16和sRAGE对ARDS的诊断和预后评估有临床价值,联合检测对早期预测ARDS和预后优于单独检测。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To explore the clinical significance of the combined detection of Clara cell secretory protein 16 (CC16) and soluble receptor for advanced glycation end product (sRAGE) in the diagnosis and prognosis of acute respiratory distress syndrome (ARDS).

METHODS: 100 ARDS patients admitted to the intensive care unit (ICU) of Chu Hsien-I Memorial Hospital of Tianjin Medical University from July 2019 to September 2020 were enrolled as the ARDS group, and 100 non-ARDS patients admitted to the ICU during the same period were enrolled as the control group. The general information, vital signs, blood gas analysis, serum CC16 and sRAGE levels, duration of mechanical ventilation, length of ICU stay and prognosis during hospitalization were collected. The receiver operating characteristic (ROC) curve was drawn and the area under ROC curve (AUC) was calculated to evaluate the clinical value of CC16 and sRAGE lonely or combination in the diagnosis and prognosis of ARDS.

RESULTS: The duration of mechanical ventilation in the ARDS group was significantly longer than that in the non-ARDS group (days: 15.44±3.04 vs. 12.61±3.73, P < 0.01), and the hospitalization mortality was higher (38.0% vs. 9.0%, P < 0.01), but there was no significant difference in gender, age, body mass index (BMI), acute physiology and chronic health evaluation II (APACHE II) score or the length of ICU stay between the two groups. There were 62 ARDS patients survived and 38 ARDS patients died during hospitalization. The APACHE II score of the death group was significantly higher than that of the survival group (23.55±2.83 vs. 19.40±4.10, P < 0.01), but there was no significant difference in age, BMI, oxygenation index, mean arterial pressure, duration of mechanical ventilation or the length of ICU stay between the two groups. The serum levels of CC16 and sRAGE in the ARDS group were significantly higher than those in the non-ARDS group [CC16 (mg/L): 38.78±14.70 vs. 21.87±2.45, sRAGE (pg/L): 2 470.95±288.70 vs. 2 013.22±131.15, both P < 0.01]; and the serum levels of CC16 and sRAGE of ARDS patients in the death group were significantly higher than those in the survival group [CC16 (mg/L): 42.02±10.81 vs. 30.52±9.47, sRAGE (pg/L): 2 638.34±324.07 vs. 2 279.91±163.70, both P < 0.01]. ROC curve showed that the AUC of CC16 and sRAGE in the diagnosis of ARDS alone were 0.859 [95% confidence interval (95%CI) was 0.808-0.911] and 0.821 (95%CI was 0.762-0.879), and the best cut-off values were 25.76 mg/L and 2 203.00 pg/L, respectively; the AUC of combined detection of CC16 and sRAGE was 0.932 (95%CI was 0.900-0.965) with the sensitivity of 89.0% and the specificity of 87.6%. The AUC of CC16 and sRAGE in predicting the death of patients with ARDS during hospitalization were 0.747 (95%CI was 0.651-0.843) and 0.819 (95%CI was 0.737-0.902), and the best cut-off values were 32.95 mg/L and 2 554.50 pg/L, respectively; the AUC of combined detection of CC16 and sRAGE was 0.900 (95%CI was 0.828-0.972) with the sensitivity of 88.7% and the specificity of 84.5%.

CONCLUSIONS: Serum CC16 and sRAGE have clinical value for the diagnosis and prognosis of ARDS. The combined detection of them is superior to individual detection for early prediction of ARDS and prognosis.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Gao Y, Li J. [Significance of combined application of biomarkers in the diagnosis and prognosis assessment of patients with acute respiratory distress syndrome]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021. PMID: 33565404. doi:10.3760/cma.j.cn121430-20201021-00592

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。